Analysts Provide Mixed Views on Myriad After Supreme Court Agrees to Rehear Patent Case | GenomeWeb

NEW YORK (GenomeWeb News) – Wall Street analysts took a mixed view of Myriad Genetics today following the announcement on Friday by the US Supreme Court that it would review a lawsuit challenging the company's patents related to the BRCA1 and BRCA2 genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.